Ronen Kantor - XTL Biopharmaceutica Company Sec
XTLB Stock | ILS 6.70 0.20 3.08% |
Insider
Ronen Kantor is Company Sec of XTL Biopharmaceuticals
Phone | 972 3 611 6600 |
Web | https://www.xtlbio.com |
XTL Biopharmaceutica Management Efficiency
The company has return on total asset (ROA) of (0.1001) % which means that it has lost $0.1001 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3822 %, meaning that it generated $0.3822 on every $100 dollars invested by stockholders. XTL Biopharmaceutica's management efficiency ratios could be used to measure how well XTL Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Elad Aharonson | ICL Israel Chemicals | 49 | |
Amir Meshulam | ICL Israel Chemicals | 43 | |
Aviram Lahav | ICL Israel Chemicals | 64 | |
Itay Rafael | Ratio Oil Explorations | 44 | |
Amir Brami | Ratio Oil Explorations | N/A | |
Rachel Mittelman | Azrieli Group | 45 | |
Yigal Landau | Ratio Oil Explorations | 63 | |
Eyal BenHaim | Bank Leumi Le Israel | 52 | |
Terry Yaskil | Mizrahi Tefahot | 50 | |
Shevy Shemer | Mizrahi Tefahot | 59 | |
Aya Landman | ICL Israel Chemicals | N/A | |
Yossi Shazar | Ratio Oil Explorations | N/A | |
Avraham Ortal | Bank Leumi Le Israel | 56 | |
Ziv CPA | Bank Leumi Le Israel | 52 | |
Lena Schwartz | Israel Discount Bank | N/A | |
Ofer Benyosef | Ormat Technologies | 59 | |
Noa Burla | Ratio Oil Explorations | 42 | |
Shiri Neder | Nice | 47 | |
Liran Razmovich | Israel Discount Bank | N/A | |
Liza Tavori | Ormat Technologies | N/A | |
Adi Kaplan | Israel Discount Bank | 50 |
Management Performance
Return On Equity | 0.38 | |||
Return On Asset | -0.1 |
XTL Biopharmaceuticals Management Team
Elected by the shareholders, the XTL Biopharmaceutica's board of directors comprises two types of representatives: XTL Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XTL. The board's role is to monitor XTL Biopharmaceutica's management team and ensure that shareholders' interests are well served. XTL Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, XTL Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
Itay Weinstein, Chief Officer | ||
Shlomo Shalev, CEO Director | ||
Ronen Kantor, Company Sec |
XTL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is XTL Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.38 | |||
Return On Asset | -0.1 | |||
Current Valuation | 61.84 M | |||
Shares Outstanding | 514.21 M | |||
Shares Owned By Insiders | 16.20 % | |||
Price To Earning | 558.33 X | |||
EBITDA | (940 K) | |||
Net Income | 435 K | |||
Cash And Equivalents | 5.06 M | |||
Cash Per Share | 0.01 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in XTL Stock
XTL Biopharmaceutica financial ratios help investors to determine whether XTL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XTL with respect to the benefits of owning XTL Biopharmaceutica security.